Guidelines on the Prevention and Control of Tuberculosis in Ireland

More documents

Recommendations

Info

<strong>Guidelines</strong> on the Prevention and Control of Tuberculosis in Ireland 2010HSE/HPSC• Management of sputum induction to minimise risk to staff and other patients• Reducing risk associated with immunosuppressed patients.Education of patients/family/carersSee appendices 6 and 11 for patient information leaflet and hospital discharge leaflet. Some patients whoare infectious can remain at home in the household that has already been exposed, as it has been shownthat the risk of additional transmission of infection in this setting is extremely low. 52The infectious patient must be instructed to take the following precautions until advised by their doctor toreturn to normal activities:• Stay at home and not go to work, school, public places or any other locations where there willbe previously unexposed people until advised to do so by the treating clinician• No visits by previously unexposed people• No visits by children (young children living at home will be assessed by public health doctorsregarding the need for LTBI window prophylaxis)• Avoid visits by relatives or friends who are immunosuppressed• Cover their mouth and nose with a tissue when sneezing or coughing.The infectious patient must be educated regarding:• Safe disposal of tissues and the importance of hand washing after coughing/sneezing• Disease transmission and disease control• The importance of compliance with medication• Side-effects of anti-TB medication• Contact tracing.-87-
<strong>Guidelines</strong> on the Prevention and Control of Tuberculosis in Ireland 2010HSE/HPSC7. BCG VaccinationThe Bacillus Calmette-Guerin (BCG) vaccine was derived by in-vitro attenuation of the bovine tuberclebacillus between the years 1908 and 1918 in France. WHO encouraged widespread use of the vaccinestarting in the 1950s and as a result more than 70% of the world’s children now receive BCG. However,the policies on BCG vaccination differ greatly both nationally and internationally, reflecting differences ofexpert opinion as to the mechanism of action and effectiveness of the vaccine. 242 The potential loss of thetuberculin test as an indicator of natural infection with tubercle bacilli when BCG is routinely used may be adisadvantage that has to be weighed against the benefits of the vaccine.7.1 Clinical EfficacyThe clinical efficacy of a vaccine is measured in terms of the percentage reduction in disease amongvaccinated individuals that is attributed to vaccination i.e. the proportion of those vaccinated who gainprotective immunity from the vaccine. 243 BCG vaccines are generally given to protect against TB. BCGvaccine does not give 100% protection but it does protect against the more serious forms of the disease,e.g. TB meningitis especially in the young. The NICE guidelines cite evidence from both randomisedcontrolled trials and case control studies for the efficacy of BCG vaccination in infancy in preventingpulmonary TB infection, TB deaths, TB meningitis, laboratory-confirmed TB cases and disseminated TB. 26BCG vaccine is probably most consistently effective against tuberculous meningitis and miliary TB withprotection lasting approximately 15 years. It is universally agreed that BCG vaccine protects small childrenfrom severe forms of childhood TB especially in areas with a high risk of infection. 244;245 In such areas withhigh infection risk, WHO EPI programme reports a global coverage of BCG in children less than one yearat around 85%. 246An extensive study by Tala et al. attempted to interpret variations in the efficacy of BCG vaccine. Factorsconsidered to be important are age at administration, prior exposure to environmental non-tuberculousmycobacteria, efficacy of BCG vaccine including vaccine quality, host genetics and nutrition, infectionincidence, the study design and the route of administration. 247 A meta-analysis of large numbers of BCGefficacy trials revealed a protection rate against pulmonary TB of 86% in randomised trials and 75% in casecontrol studies despite extensive use of the vaccine. 40 Colditz et al. in a meta-analysis estimated the overallefficacy of BCG in preventing pulmonary TB to be approximately 50%. Against TB meningitis the efficacywas 64% and against TB deaths 71%. 248 In summary, there is overall agreement that the efficacy of BCGis at its best about 80% 249 and of 15-20 years duration. 250 Kritski et al. reported a protection rate of 69%against MDR-TB in a recent study in 1996. 2517.2 Criteria for Discontinuation of a Universal BCG Vaccination ProgrammeIn 1994, the International Union against Tuberculosis and Lung Disease (IUATLD) expert group publishedcriteria for discontinuing BCG vaccination programmes in countries with a low prevalence of TB. 252 Thesecriteria are outlined as follows:1IUATLD criteriaBefore consideration is given to whether a country stops or modifies its BCG programme, the followingrequirements must be met:• There is a well functioning TB control programme• There has been a reliable reporting system over the previous five or more years, enabling theestimation of the annual incidence of active TB by age and risk groups, with particular emphasison TB meningitis and sputum smear positive pulmonary TB. In Ireland, national data enabling adetailed epidemiological analysis for the country, as a whole was first produced by HPSC in the1998 National TB Report. The 2006 National TB Report is the ninth national TB report.• Due consideration has been given to the possibility of an increase in the incidence of TB resultingfrom the epidemiological situation of AIDS in that country.15With one of the following• The average annual notification rate of sputum smear positive pulmonary TB should be 5 per100,000 or less during the previous three years-88-
Page 2 and 3:
Guidelines on the
Page 4 and 5:
Guidelines on the
Page 6 and 7:
Guidelines on the
Page 8 and 9:
Guidelines on the
Page 10 and 11:
Guidelines on the
Page 12 and 13:
Guidelines on the
Page 14 and 15:
Guidelines on the
Page 16 and 17:
Guidelines on the
Page 18 and 19:
Guidelines on the
Page 20 and 21:
Guidelines on the
Page 22 and 23:
Guidelines on the
Page 24 and 25:
Guidelines on the
Page 26 and 27:
Guidelines on the
Page 28 and 29:
Guidelines on the
Page 30 and 31:
Guidelines on the
Page 32 and 33:
Guidelines on the
Page 34 and 35:
Guidelines on the
Page 36 and 37:
Guidelines on the
Page 38 and 39:
Guidelines on the
Page 40 and 41:
Guidelines on the
Page 42 and 43:
Guidelines on the
Page 44 and 45:
Guidelines on the
Page 46 and 47:
Guidelines on the
Page 48 and 49:
Guidelines on the
Page 50 and 51:
Guidelines on the
Page 52 and 53:
Guidelines on the
Page 54 and 55:
BGuidelines on the
Page 56 and 57: Guidelines on the
Page 70 and 71: 1♦Guidelines on
Page 98 and 99: Figure 6.1Patient placement for Pul
Page 156 and 157:
Guidelines on the
Page 158 and 159:
Guidelines on the
Page 160 and 161:
Guidelines on the
Page 162 and 163:
Guidelines on the
Page 164 and 165:
Guidelines on the
Page 166 and 167:
Guidelines on the
Page 168 and 169:
Guidelines on the
Page 170 and 171:
Guidelines on the
Page 172 and 173:
Guidelines on the
Page 174 and 175:
Guidelines on the
Page 176 and 177:
Guidelines on the
Page 178 and 179:
Guidelines on the
Page 180 and 181:
Guidelines on the
Page 182 and 183:
Guidelines on the
Page 184 and 185:
Guidelines on the
Page 186 and 187:
Guidelines on the
Page 188 and 189:
Guidelines on the
Page 190 and 191:
Guidelines on the
Page 192 and 193:
Guidelines on the
Page 194 and 195:
Guidelines on the
Page 196 and 197:
Guidelines on the
Page 198 and 199:
Guidelines on the
Page 200 and 201:
Guidelines on the
Page 202 and 203:
Guidelines on the
Page 204 and 205:
Guidelines on the
Page 206 and 207:
Guidelines on the
Page 208 and 209:
Guidelines on the
Page 210 and 211:
Guidelines on the
Page 212 and 213:
Guidelines on the
Page 214 and 215:
Guidelines on the
Page 216 and 217:
Guidelines on the
Page 218:
25-27 Middle Gardiner Street Dublin
show all

Guidelines on the Prevention and Control of Tuberculosis in Ireland

Create successful ePaper yourself

Delete template?

Save as template?